These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24330088)

  • 1. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 2. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib: osteonecrosis of the jaw.
    Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
    JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
    Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib stimulates human skin type mast cell degranulation and maturation.
    Mizukami Y; Sugawara K; Kira Y; Tsuruta D
    J Dermatol Sci; 2017 Dec; 88(3):308-319. PubMed ID: 28843624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 12. Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy.
    Thiem A; Mergler R; Kneitz H; Weyandt G; Goebeler M; Gesierich A
    J Dtsch Dermatol Ges; 2016 Apr; 14(4):427-8. PubMed ID: 27027759
    [No Abstract]   [Full Text] [Related]  

  • 13. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
    Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
    Borgia F; Saitta C; Vaccaro M; Franzè MS; Lentini M; Cannavò SP
    Int J Immunopathol Pharmacol; 2017 Sep; 30(3):327-331. PubMed ID: 28825507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case of sorafenib-induced thyroid storm.
    Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
    J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
    Musri FY; Mutlu H; Kıvrak Salim D; Karakurt Eryılmaz M; Ünal B; Tural D; Şenol Coşkun H
    J Oncol Pharm Pract; 2016 Apr; 22(2):350-3. PubMed ID: 25567520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic atrophy--a new late toxic effect of sorafenib.
    Hescot S; Vignaux O; Goldwasser F
    N Engl J Med; 2013 Oct; 369(15):1475-6. PubMed ID: 24106956
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.